XXXX after orthotopic liver transplantation: treatment with the Amplatzer vascular plug.

@entity1 @entity882 @entity648 @entity409 @entity432 @entity99
PURPOSE: To evaluate the safety and efficacy of the Amplatzer vascular plug (AVP) for embolization of the splenic artery in @entity1 with @entity99 after orthotopic liver transplantation (OLT). MATERIALS AND METHODS: Thirteen @entity1 (9 @entity1 and 4 @entity1 ) with a mean age of 56 years (range 22-70) who developed @entity432 after OLT with decreased liver perfusion and clinically relevant @entity409 (increased transaminase or serum @entity648 levels, @entity882 , and/or therapy-refractory ascites) were treated by embolization of the proximal third of the splenic artery using the AVP. The plugs ranged in diameter from 6 to 16 mm, and they were introduced through femoral (n = 9), axillary (n = 3), or brachial (n = 1) access using a 5F or 8F guiding catheter. RESULTS: The plugs were successfully placed, and @entity432 was achieved in all @entity1 . Placement of two plugs was necessary for complete occlusion in 3 of the 13 @entity1 . Occlusion took on average 10 min (range 4-35). There was no nontarget embolization or plug migration into more distal segments of the splenic artery. All @entity1 showed improved arterial perfusion, including the liver periphery, on postinterventional angiogram. After embolization, liver function parameters (transaminase and @entity648 levels) improved with normalization of concomitant @entity882 and a decrease in ascites volume. CONCLUSION: Our initial experience in a small @entity1 population with SAS suggests that the AVP enables precise embolization of the proximal splenic artery, thus providing safe and effective treatment for poor liver perfusion after OLT due to SAS.
